For the quarter ended December 2025, Myriad Genetics (MYGN Quick QuoteMYGN - Free Report) reported revenue of $209.8 million, down 0.4% over the same period last year. EPS came in at $0.04, compared to $0.03 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $207.59 million, representing a surprise of +1.07%. The company delivered an EPS surprise of +350%, with the consensus EPS estimate being -$0.02.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Myriad performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue by core product- Prenatal: $44.9 million versus the two-analyst average estimate of $47.02 million. The reported number represents a year-over-year change of 0%.
• Revenue by core product- Hereditary Cancer: $96.8 million compared to the $94.87 million average estimate based on two analysts. The reported number represents a change of +2.7% year over year.
• Revenue by core product- Tumor Profiling: $31.5 million versus the two-analyst average estimate of $28.59 million. The reported number represents a year-over-year change of +2.3%.

View all Key Company Metrics for Myriad here>>>

Shares of Myriad have returned -26.9% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.